Skip to content

Alumis Inc. ALMS Increase Decrease In Research And Development Accrued Expenses

Increase Decrease In Research And Development Accrued Expenses at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$12.99M+2,124%
Disc Medicine logo
Disc MedicineIRON
$686K+145%
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
$86K
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$5.99M-130%
PRD
Perdoceo EducationPRDO
$2.48M+272%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$54.43M+61.8%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept alms:IncreaseDecreaseInResearchAndDevelopmentAccruedExpenses.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s increase decrease in research and development accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s increase decrease in research and development accrued expenses?
Alumis Inc. (ALMS) reported increase decrease in research and development accrued expenses of $1.18M in Q1 2026.
How has Alumis Inc.'s increase decrease in research and development accrued expenses changed year-over-year?
Alumis Inc.'s increase decrease in research and development accrued expenses decreased by 78.8% year-over-year, from $5.55M to $1.18M.
What does increase decrease in research and development accrued expenses mean?
Represents the change in liabilities related to R&D activities that have been incurred but not yet paid in cash. An increase indicates that the company is deferring cash outflows for research, effectively providing a short-term source of liquidity.